Camlin Fine Sciences profit and loss

Latest FY26

Revenue: ₹1,723cr+3.4% on FY25
EBITDA: ₹107cr−48.6% on FY25
Net profit: ₹23.5cr−₹158 cr in FY25
EPS: ₹1.46−₹8.03 in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	1,862	1,723	1,667	1,613	1,682	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	32.8	28.8	14.5	15.6	5.8
	1,894	1,752	1,681	1,629	1,687
	910	823	786	747	856
	69.6	88.6	118	114	60.7
	39.8	10.6	−54.5	52.7	−103
	263	244	192	179	163
	74.2	72.9	99.9	60.3	58.5
	75.5	70.9	63.8	78.6	62.5
	493	450	417	447	500
	1,926	1,760	1,622	1,678	1,597
	85.9	107	208	73.9	205
	10.4	36.0	144	−4.7	143
Profit
	−31.1	−8.2	58.8	−49.4	90.1
	−36.6	−25.5	−9.8	−49.8	−9.7
	−67.6	−33.6	49.0	−99.2	80.4
	15.8	17.9	42.1	24.9	28.7
	−16.5	−18.4	−42.1	−19.2	11.9
	−0.7	−0.5	0.1	5.6	40.6
	2.2	1.7	0.4	0.0	0.0
	0.6	23.5	−158	−105	39.8
	−66.9	−33.2	49.0	−105	39.8
	65.3	55.1	−208	0.0	0.0
	8.8	3.4	−12.2	18.0	20.2
	9.4	27.0	−170	−86.9	60.0
	5.9	27.6	−139	−92.8	52.1
	−5.3	−4.1	−19.1	−12.1	−12.3
Per share
	₹0.27	₹1.46	−₹8.03	−₹5.58	₹3.45
	₹0.22	₹1.42	−₹7.94	−₹5.50	₹3.41
Continuing & discontinued operations
	65.5	55.2	−208	0.0	0.0
	0.2	0.2	0.0	0.0	0.0
Other comprehensive income — detail
	8.8	3.4	−12.2	—	—
	−0.3	−0.1	−0.1	−0.1	−0.9
	−0.1	−0.1	−0.0	—	—
	—	—	—	−0.0	−0.3
	8.5	1.0	−12.4	18.0	20.8
	−0.5	−2.5	−0.2	—	—
	—	—	—	0.0	−0.0
	18.8	34.7	−151	−74.4	72.5
	−9.5	−7.8	−19.1	−12.5	−12.4
Per share — as-filed variants
	−₹3.00	−₹1.59	₹2.89	−₹5.58	₹3.45
	−₹3.00	−₹1.59	₹2.86	−₹5.50	₹3.41
	₹3.27	₹3.05	−₹10.92	₹0.00	₹0.00
	₹3.22	₹3.01	−₹10.80	₹0.00	₹0.00
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	843	801	817	699	868
	45.3%	46.5%	49.0%	43.4%	51.6%
Adjusted (ex-exceptional items) — derived
	−31.1	−8.2	58.8	−49.4	90.1
	−36.6	−25.5	−9.8	−49.8	−9.7
	36.8	48.7	−148	−55.1	44.6
	₹16.48	₹3.02	−₹7.53	−₹2.93	₹3.87

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

CAMLINFINE₹82.32

Camlin Fine Sciences Limited

· Chemicals

Annual Quarterly₹ CrorePeersCLEAN DEEPAKNTR BAYERCROP TIRUMALCHM ATUL SHK PAUSHAKLTD ANURASMcap ₹1,581 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	1,681.6	1,613.1	1,666.5	1,723.3	1,861.7
Other Income	5.8	15.6	14.5	28.8	32.8
Total Income	1,687.4	1,628.6	1,681.0	1,752.1	1,894.5
Expenses
+ Cost of Materials Consumed	855.6	746.6	786.3	823.3	909.8
+ Purchases of Stock-in-Trade	60.7	114.3	117.5	88.6	69.6
+ Changes in Inventories	-103.0	52.7	-54.5	10.6	39.8
+ Employee Benefit Expense	162.6	178.7	192.3	243.9	263.4
+ Finance Costs	58.5	60.3	99.9	72.9	74.2
+ Depreciation & Amortisation	62.5	78.6	63.8	70.9	75.5
+ Other Expenses	500.4	446.8	416.9	450.1	493.2
Total Expenses	1,597.3	1,678.1	1,622.1	1,760.3	1,925.6
EBITDA	205.3	73.9	208.1	106.9	85.9
EBIT	142.8	-4.7	144.3	36.0	10.4
Profit
PBT before Exceptional Items	90.1	-49.4	58.8	-8.2	-31.1
+ Exceptional Items	-9.7	-49.8	-9.8	-25.5	-36.6
Pretax Income	80.4	-99.2	49.0	-33.6	-67.6
+ Current Tax	28.7	24.9	42.1	17.9	15.8
+ Deferred Tax	11.9	-19.2	-42.1	-18.4	-16.5
Tax Expense	40.6	5.6	0.1	-0.5	-0.7
+ Share of Associates & JVs	0.0	0.0	0.4	1.7	2.2
Net Income	39.8	-104.9	-158.1	23.5	0.6
+ Net Income — Continuing Ops	39.8	-104.9	49.0	-33.2	-66.9
+ Net Income — Discontinued Ops	0.0	0.0	-207.5	55.1	65.3
+ Other Comprehensive Income	20.2	18.0	-12.2	3.4	8.8
Total Comprehensive Income	60.0	-86.9	-170.4	27.0	9.4
Net Income to Common	52.1	-92.8	-139.0	27.6	5.9
Minority Interest	-12.3	-12.1	-19.1	-4.1	-5.3
Per Share
Basic EPS	3.45	-5.58	-8.03	1.46	0.27
Diluted EPS	3.41	-5.50	-7.94	1.42	0.22
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax	0.0	0.0	-207.5	55.2	65.5
+ Tax — Discontinued Operations	0.0	0.0	0.0	0.2	0.2
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-12.2	3.4	8.8
+ Items NOT to be Reclassified to P&L	-0.9	-0.1	-0.1	-0.1	-0.3
+ Tax on Items NOT to be Reclassified	—	—	-0.0	-0.1	-0.1
+ Tax on Items NOT to be Reclassified — alt tag	-0.3	-0.0	—	—	—
+ Items to be Reclassified to P&L	20.8	18.0	-12.4	1.0	8.5
+ Tax on Items to be Reclassified	—	—	-0.2	-2.5	-0.5
+ Tax on Items to be Reclassified — alt tag	-0.0	0.0	—	—	—
Comprehensive Income — Owners of Parent	72.5	-74.4	-151.3	34.7	18.8
Comprehensive Income — Non-controlling Interests	-12.4	-12.5	-19.1	-7.8	-9.5
Per Share — as-filed variants
Basic EPS — Continuing Operations	3.45	-5.58	2.89	-1.59	-3.00
Diluted EPS — Continuing Operations	3.41	-5.50	2.86	-1.59	-3.00
Basic EPS — Discontinued Operations	0.00	0.00	-10.92	3.05	3.27
Diluted EPS — Discontinued Operations	0.00	0.00	-10.80	3.01	3.22
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	868.3	699.4	817.3	800.9	842.5
Gross Margin %	51.64	43.36	49.04	46.47	45.25
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	90.1	-49.4	58.8	-8.2	-31.1
− Exceptional Items (reconciliation)	-9.7	-49.8	-9.8	-25.5	-36.6
Net Income Adj (tax-effected)	44.6	-55.1	-148.3	48.7	36.8
EPS Adj	3.87	-2.93	-7.53	3.02	16.48
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00
Filed Debt Equity	—	0.00	72.00	—	—
Filed Dscr	—	0.00	1.00	—	—
Paid Up Equity Capital	15.7	16.7	18.8	19.2	19.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.